1. Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study.
- Author
-
Martra F, Kunos C, Gibbons H, Zola P, Galletto L, DeBernardo R, and von Gruenigen V
- Subjects
- Aged, Body Mass Index, Case-Control Studies, Endometrial Neoplasms surgery, Female, Humans, Hysterectomy methods, International Cooperation, Logistic Models, Lymph Node Excision statistics & numerical data, Middle Aged, Obesity diagnosis, Probability, Proportional Hazards Models, Radiotherapy, Adjuvant, Reference Values, Retrospective Studies, Risk Assessment, Survival Analysis, Treatment Outcome, Cause of Death, Endometrial Neoplasms mortality, Endometrial Neoplasms radiotherapy, Lymph Nodes pathology, Obesity mortality
- Abstract
Objective: The purpose of this study was to determine the impact of patient weight on the frequency of surgical staging lymphadenectomy and pelvic radiation. Adverse effects, disease relapse, and survival outcomes were investigated., Study Design: Records of 766 women who underwent surgery for presumed corpus-confined endometrial cancer were reviewed. Body mass index (BMI) was calculated to categorize women as obese (BMI, > or = 30 kg/m2) or nonobese (BMI, < 30 kg/m2). Radiation-related toxicity was scored retrospectively. Median duration of follow-up period was 38 months. Chi2, logistic regression, correlation, Kaplan-Meier, and Cox multivariate proportional hazards were used for analysis., Results: Lymphadenectomy was completed as often in nonobese as obese women (P = .24). Adjuvant pelvic radiation treatment was administered more often in nonobese women (P = .01). Among 681 women with endometrioid histopathologic findings, 4-year cancer-related survival in obese women was 10% higher than all cause deaths, compared with 6% in nonobese women., Conclusion: Obesity was not a barrier to lymphadenectomy, but did influence adjuvant pelvic radiation use.
- Published
- 2008
- Full Text
- View/download PDF